scholarly journals Marginal zone dural lymphoma: the Memorial Sloan Kettering Cancer Center and University of Miami experiences

2016 ◽  
Vol 58 (4) ◽  
pp. 882-888 ◽  
Author(s):  
Macarena I. de la Fuente ◽  
Aya Haggiagi ◽  
Adrienne Moul ◽  
Robert J. Young ◽  
Charif Sidani ◽  
...  
2017 ◽  
Vol 3 (4) ◽  
pp. 389-399 ◽  
Author(s):  
Alexandra Gomez ◽  
Vincent DeGennaro ◽  
Sophia H.L. George ◽  
Isildinha M. Reis ◽  
Estefania Santamaria ◽  
...  

Purpose We compared a cohort of Haitian immigrants with residents in Haiti with breast cancer (BC) to evaluate the effects of location on presentation, treatment, and outcomes. Patients and Methods Participants were Haitian women with BC living in Miami who presented to the University of Miami/Jackson Memorial Hospital and women with BC living in Haiti who presented to the Innovating Health International Women’s Cancer Center. The primary outcome was the relationship between location, cancer characteristics, and survival. The secondary objective was to compare our results with data extracted from the SEER database. Cox regression was used to compare survival. Results One hundred two patients from University of Miami/Jackson Memorial Hospital and 94 patients from Innovating Health International were included. The patients in Haiti, compared with the patients in Miami, were younger (mean age, 50.2 v 53.7 years, respectively; P = .042), presented after a longer duration of symptoms (median, 20 v 3 months, respectively; P < .001), had more advanced stage (44.7% v 25.5% with stage III and 27.6% v 18.6% with stage IV BC, respectively), and had more estrogen receptor (ER) –negative tumors (44.9% v 26.5%, respectively; P = .024). The percentage of women who died was 31.9% in Haiti died compared with 17.6% in Miami. Median survival time was 53.7 months for women in Haiti and was not reached in Miami. The risk of death was higher for women in Haiti versus women in Miami (adjusted hazard ratio, 3.09; P = .0024). Conclusion Women with BC in Haiti experience a significantly worse outcome than immigrants in Miami, which seems to be related to a more advanced stage and younger age at diagnosis, more ER-negative tumors, and lack of timely effective treatments. The differences in age and ER status are not a result of access to care and are unexplained.


2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 8554-8554
Author(s):  
Adam Starr ◽  
PingFu Fu ◽  
Paolo Fabrizio Caimi ◽  
Erica Leigh Campagnaro ◽  
Brenda W. Cooper ◽  
...  

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 5099-5099
Author(s):  
Jose Carlos Revilla Lopez ◽  
Jorge A Benavides vasquez ◽  
Lina P Huerta Saenz

Abstract Abstract 5099 Non-Gastric Marginal Zone B-Cell Lymphoma of Mucosa-Associated Lymphoid Tissue in a Peruvian Referral Cancer Center (Instituto Nacional de Enfermedades Neoplasicas) Jose C. Revilla, MD1, Jorge A. Benavides, MD, Lina Huerta-Saenz, MD*,2. 1Oncological Medicine Deparment, Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru,2Albert Einstein Medical Center, Philadelphia, PA, USA Historically, non-gastric marginal zone MALT lymphomas have been difficult to characterize because of their wide anatomical distribution. Previous studies have shown broad distribution patterns with different clinical courses and responses to therapy. There are still questions regarding which could be the best clinical management and this remains without a conclusive answer. A retrospective 10-year study from 1997 to 2007 of patients with diagnosis of non-gastric marginal zone B-cell lymphoma of mucosa-associated lymphoma tissue (MALT) was performed in a Peruvian referral cancer center. To be eligible for the study, all patients had to have pathological confirmation of diagnosis with a clinically dominant non-gastric site of localization. Disease stage was defined according to the Ann Arbor staging criteria, Zubrod performance status scale and location of extranodal disease. Serum lactate dehydrogenase (LDH) and β2-microglobulin levels were used for laboratory monitoring. Bone marrow compromise was also evaluated. All data regarding medical treatment, response to treatment, failure, death and disease status at last follow-up were obtained. The results showed 23 patients with confirmed diagnosis, 74% of whom were female, and the mean age at time of diagnosis was 52 years old. The clinical predominant disease stages at the time of diagnosis were Ann Arbor stage I or II (76%). B-symptoms were present in 35% of the patients and only 13% of them had increased LDH levels. Bone marrow compromise was not present in the majority of patients (96%) and 75% of them had a low international prognostic index (IPI) score. The predominant anatomical location was the conjunctiva (39.1%) followed by the lung (13.1%). These findings were different from previous studies in European and North American populations where the salivary glands were the most common location. Ethnicity may be proposed as a factor related to these differences in anatomical location patterns. Regarding medical management, chemotherapy was the first-line of treatment and anthracyclines were the agents predominantly used (47.8% of patients). Radiotherapy alone was given to 18.2% of patients during the study and combinations of chemotherapy and radiotherapy were used in 4.6% of patients. Follow-up was completed for an average of 25.1 months (range=14.3-35.9 mo), with a complete response to the treatment in 56.6% of patients. Hashimoto's thyroiditis and hepatitis C were the only concomitant medical conditions reported for one patient each, respectively. The survival curve did not show significant differences by gender (p<0.05). In this study, non-gastric B-cell lymphoma of mucosa-associated lymphoma tissue (MALT) showed an indolent clinical course with female predominance and early stages at time of diagnosis. Ocular conjunctiva was the most common location and most of the patients showed good clinical response to the first-line chemotherapy treatment; additionally, there was a low associated mortality rate. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 922-922
Author(s):  
Apostolia-Maria Tsimberidou ◽  
Daniel Catovsky ◽  
Ellen Schlette ◽  
Susan O’Brien ◽  
Hagop Kantarjian ◽  
...  

Abstract Purpose: The optimal management of splenic marginal zone lymphoma (SMZL) or marginal-zone leukemia/lymphoma (MZL) is controversial. We retrospectively assessed the clinical outcome of patients with SMZL/MZL treated with systemic therapy. Patients and Methods: Patients were assessed by the time of their first treatment at U. T. M. D. Anderson Cancer Center, Dept. of Leukemia (5/95 to 10/04). Diagnosis was confirmed in 70 patients by slide review. The indications for treatment were the same as those used for patients with CLL. Results: The median age was 64 years (range, 33–88); and 61% of patients had monoclonal gammopathy. The median number of CD20 molecules/cell was 65.2 x 103 (16–260 x 103). Of the patients who required systemic therapy, 26 were treated with immunotherapy (rituximab, 25; alemtuzumab, 1); 6 with chemoimmunotherapy (CI/T; rituximab combined with a fludarabine-based regimen); and 11 with chemotherapy (C/T). Ten patients had splenectomy, and 17 were in the observation group. The overall response rates were 88% (CR, 31%) in the immunotherapy group, 83% (CR, 17%) in the CI/T group, and 55% (CR, 18%) in the C/T group. The median follow-up was 2.7 years. Patients treated with immunotherapy +/− C/T had higher rates of overall and failure-free survival compared with those treated with C/T. Figure Figure In univariate analysis, the only factors predicting longer survival were age &gt;60 years (p=0.01) and immunotherapy +/− chemotherapy (p=0.04). Seventeen (24%) of 70 patients had other malignancies prior to (n=8) or after (n=8) treatment of SMZL/MZL or both (n=1). Changes in bone marrow and blood counts in patients treated with rituximab (n=25) were compared with those of patients who had splenectomy as initial therapy (n=17, including 7 who had subsequent therapies). Rituximab resulted in the disappearance of a palpable spleen (median size, 6 cm; range 0–20cm) in 23 (92%) patients. Rituximab was superior to splenectomy in normalizing the white blood cell (WBC) counts (p&lt;0.001) and absolute lymphocyte counts (ALC)(p&lt;0.001). Splenectomy resulted in higher platelet counts compared with rituximab, but platelet counts remained within the normal range in all patients treated with rituximab. Hemoglobin levels and bone marrow cellularity did not reach statistical significance, but there was a trend towards a significantly lower proportion of lymphocytes in patients treated with rituximab (p=0.1). Conclusions: Rituximab with or without C/T induces durable remissions and prolongs survival in patients with SMZL/MZL, probably because CD20 molecules/cell are higher in SMZL/MZL than in CLL. Our data demonstrate that rituximab effectively controls SMZL, as evidenced by improvement in WBC and ALC and splenomegaly, and may be the treatment of choice, at least in older SMZL patients with comorbid diseases. Clinical trials of immunotherapy or CI/T are warranted.


2020 ◽  
Vol 20 ◽  
pp. S284
Author(s):  
Rodrigo Castillo-Llanos ◽  
Rosana Cordova Córdova Serrano ◽  
Ana Florencia Ramírez-Ibarguen

2021 ◽  
Vol 15 (4) ◽  
Author(s):  
Yutaka Tsutsumi ◽  
Shinichi Ito ◽  
Jun Nagai ◽  
Takahiro Tateno ◽  
Takanori Teshima
Keyword(s):  

2011 ◽  
Vol 2011 ◽  
pp. 1-5 ◽  
Author(s):  
Rabih Said ◽  
Sanaa Rizk ◽  
Qun Dai

Primary dural lymphoma is a rare disease with more indolent clinical behavior compared to primary central nervous system lymphoma. The majority of the reported cases were indolent marginal zone lymphoma subtype with more predilections to the spine. Herein, we are presenting a case of intracranial, diffuse large B-cell lymphoma of the dura that was diagnosed and treated at our institution. We are presenting the challenges in the treatment based on a review of the literature.


Sign in / Sign up

Export Citation Format

Share Document